Background: Osteogenesis Imperfecta (OI) is a genetic disease characterized by skeletal fragility. Collagen type 1 is found in many tissues and collagen abnormalities may result in organ specific symptomatology. Musculoskeletal pain is a known issue for patients with OI, osteoarthritis (OA) can be a likely cause. Only few studies have investigated the relationship between OI and OA but demonstrated a greater propensity in OI patients to develop rapidly progressing OA. Therefore, we wanted to investigate if OA is more frequent in patients with OI compared to the general population. Objective: To evaluate the risk of osteoarthritis in patients with OI. Design: A Danish nationwide, population-based and register-based longitudinal open cohort study. Participants: From 1977 to 2019, all patients registered with an OI diagnosis and a reference population matched on age and sex 5:1. Measurements: Sub-hazard ratios for any, hip, and knee osteoarthritis comparing the OI cohort to the reference population. Results: We identified 907 patients with OI (493 women) and included 4535 patients in the reference population (2465 women). The Sub Hazard Ratio was 2.20 [95% CI 1.73–2.79] for any osteoarthritis with 11.4% of the OI population and 5.4% of the reference population being registered. We found lower incidences of upper extremity joint OA compared to lower joint OA, but upper extremity joint OA was significantly more frequent in the OI population 2.1% vs 0.6%, SHR 3.19 [95% CI 1.78–5.70]. Conclusion: Patients with OI have a higher risk of OA than the reference population. Miniabstract: Osteogenesis Imperfecta (OI) is a hereditary connective tissue disorder with skeletal fragility and extraskeletal manifestations. Osteoarthritis is a frequent joint disease and the incidence increases with age. In a population-register-based study, the risk of osteoarthritis was higher in patients with OI at an earlier age compared to a reference population.
Bibliografisk noteFunding Information:
Jane Dahl Andersen, Lars Folkestad, Jannie Dahl Hald and Torben Harsløf, declare that they have no conflict of interest in relation to the work presented in this manuscript. Bente Langdahl declares speaker fees or consulting fees from UCB, Amgen, Eli Lilly, Gedeon-Richter, and Gilead and institutional research grants from Amgen and Novo Nordisk outside the current work. Bo Abrahamsen declares speaker fees or consulting fees from UCB, MSD, Amgen, Kyowa-Kirin and Pharmacosmos and institutional research grants from Novartis, UCB, Kyowa-Kirin and Pharmacosmos, outside the current work.